Released Aug 15, 2011, after the close
10-Q filed Aug 22, 2011, 53 days after period end · 0001193805-11-001610
Q2 2011 · 10-Q
Revenue$4.99M$4.99M +16.8% vs Q2 2010−16.0% vs Q1 2011
Net Income-$1.65M-$1.65M N/M vs Q2 2010N/M vs Q1 2011
EPS Diluted-$0.12-$0.12 N/M vs Q2 2010N/M vs Q1 2011
Gross Profit$1,772,042+16.2%
Operating Income$229,569−75.0%
Operating Cash Flowderived$1,792,425—
Free Cash Flowderived$1,903,376—
Margins · derived
Gross margin35.5%−0.2 pt vs Q2 2010
Operating margin4.6%−16.9 pt vs Q2 2010
Net margin-33.1%−46.4 pt vs Q2 2010
What the release said
The release
Same quarter
| Metric | Q2 2011 | Q2 2010 |
|---|---|---|
| Revenue | $4.99M | $4.27M |
| Net Income | -$1.65M | $568.26K |
| EPS Diluted | -$0.12 | $0.07 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Tanke Biosciences Corp · CIK 1452011 · Engraved from SEC EDGAR